Faculty

William E. Boden, MD, FACC, FAHA

Default Biography Avatar
Professor of Medicine, Boston University School of Medicine, Boston, MA
Lecturer in Medicine, Harvard Medical School, Scientific Director, Clinical Trials Network, VA New England Health Care System, Boston, MA

Dr. William E. Boden is Professor of Medicine at Boston University School of Medicine and Lecturer in Medicine, Harvard Medical School, in Boston, Massachusetts. In July 2016, Dr. Boden returned to the VA Boston Healthcare System to assume new duties as the Physician Research Lead for the New England VA Healthcare System and as the Scientific Director of the Clinical Trials Network, which is based at the VA Boston campus. Dr. Boden received his M.D. degree from State University of New York, Upstate Medical University, Syracuse, N.Y. in 1974. He performed his Internal Medicine residency training at Boston University Medical Center, followed by fellowship training in Cardiology at Tufts University School of Medicine in Boston, Massachusetts. He is board-certified in both Internal Medicine and in the subspecialty of Cardiovascular Disease. Since 1979, Dr. Boden has held university academic appointments at Brown University, Wayne State University, Tufts New England Medical Center, Boston University, the University of Connecticut, State University of New York in Buffalo, Albany Medical College, and currently at Boston University School of Medicine and Harvard Medical School. From 1989-2016, Dr. Boden held academic leadership positions as Chief of Cardiology or Chief of Medicine in both VA and non-VA academic centers. Dr. Boden’s principal research interests include studies in stable ischemic heart disease, post-myocardial infarction (MI) secondary prevention, acute coronary syndromes, and dyslipidemia in post-MI and coronary artery disease (CAD). He has worked extensively in the clinical trials arena of non-ST-segment elevation MI and in assessing the role of calcium antagonists in patients with ischemic heart disease, notably in non-Q-wave MI secondary prevention. Dr. Boden has been involved in clinical research investigator activities as the project director, study chairman and co-chairman for multicenter clinical trials, and served as a principal investigator, steering committee member, and consultant for numerous clinical research grant activities funded by the Department of Veterans Affairs, the NIH, and industry. He was the study chairman for the VANQWISH, INTERCEPT, and more recently, the landmark COURAGE Trial (the largest randomized trial comparison of percutaneous coronary intervention [PCI] versus optimal medical therapy in stable CAD patients). He is also the study co-chairman of the NIH-funded AIM-HIGH trial evaluating the long-term role of combination dyslipidemic therapy (niacin and statin vs statin) in CAD patients with low HDL-cholesterol, and is a national co-PI on the NIH-funded ISCHEMIA Trial, a large prospective, international RCT in over 5,100 patients with moderate to severe ischemia which has been underway since 2013 and will conclude in 2019. Dr. Boden has lectured widely (both nationally and internationally) and has written over 450 peer-reviewed publications, original articles, books, chapters, and abstracts. He has been selected as one of the Best Doctors in America continuously since 2003. He is a member of several professional Cardiology organizations and editorial boards of Journal of the American College of Cardiology, American Journal of Cardiology, Journal of Cardiovascular Pharmacology and Therapeutics, American Journal of Medicine, World Journal of Cardiology, and Clinical Cardiology. Dr. Boden also serves as an ad hoc journal reviewer for New England Journal of Medicine, Journal of the American Medical Association, Journal of the American College of Cardiology, Circulation, American Heart Journal, the Lancet, Annals of Internal Medicine, and JAMA Internal Medicine.


Recent & Upcoming Conference Sessions

Boston skyline, home of Pri-Med’s CME conference in Boston, MA

Pri-Med East

Wednesday, December 4, 2019

9:45 AM - 10:45 AM New Approaches to Manage ASCVD Risk beyond LDL-C

Grand Ballroom East, Level 3